Wednesday, July 5, 2017
ViraCyte Gets NIH, FDA Award For $3.75M
Houston-based biopharmaceutical startup ViraCyte said this morning that it has received a $3.75M award from the National Institutes of Health (NIH) and the Food and Drug Administration (FDA). The company said the award will go towards advancing its T cell immunotherapies, which are aimed at treating severe infections. The award includes $3.0M from the NIH National Heart, Lung and Blood Institute (NHLBI), under a Phase IIB SBIR award, and $750,000 in the form of a $750,000 Orphan Products Clinical Trials Grant by the FDA Office of Orphan Product Development (OOPD).